BRCA2 Polyklonaler Antikörper

BRCA2 Polyklonal Antikörper für WB, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, ELISA

Konjugation

Unkonjugiert

Publikationen

4

Kat-Nr. : 29450-1-AP

Synonyme

BRCA2, BRCC2, breast cancer 2, early onset, BROVCA2, FACD, FAD, FAD1, FANCB, FANCD, FANCD1

---

Galerie der Validierungsdaten

• 

  WB analysis using 29450-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 29450-1-AP (BRCA2 antibody) at dilution of 1:4000 incubated at room temperature for 1.5 hours.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: HeLa-Zellen, HepG2-Zellen, MCF-7-Zellen

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:1000-1:8000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• WB: See 4 publications below

Produktinformation

29450-1-AP bindet in WB, ELISA BRCA2 und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• In Publikationen genannte Reaktivität: human
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: BRCA2 fusion protein Ag31064
• Vollständiger Name: breast cancer 2, early onset
• Berechnetes Molekulargewicht: 384 kDa
• Beobachtetes Molekulargewicht: 384 kDa
• GenBank-Zugangsnummer: NM_000059
• Gene symbol: BRCA2
• Gene ID (NCBI): 675
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.
• Lagerungsbedingungen: Bei -20℃ lagern. Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

BRCA2, also named as FACD and FANCD1, is involved in double-strand break repair and/or homologous recombination. BRCA2 may participate in S phase checkpoint activation. Defects in BRCA2 are a cause of genetic susceptibility to breast cancer (BC) which also called susceptibility to familial breast-ovarian cancer type 2 (BROVCA2).

Publikationen

Species	Application	Title
human	WB	Int J Mol Sci; CSB Regulates Pathway Choice in Response to DNA Replication Stress Induced by Camptothecin; Authors - Nicole L Batenburg
human	WB	Aging (Albany NY); A prognostic risk model for programmed cell death and revealing TRIB3 as a promising apoptosis suppressor in renal cell carcinoma; Authors - Qingfeng Fu
human	WB	Prostate; Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH; Authors - Taihao Chang
human	WB	Oncogene; The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2; Authors - Yingwei Li